Background: heart failure is a complex syndrome and also one of the common reasons for readmission following discharge. This condition imposes an enormous economic burden on healthcare sectors. The present research aimed to study the establishment of a home care system for patients with heart failure in order to evaluate the cost-effectiveness of this system and patient satisfaction. Methods: The present health system research selected 40 patients as the sample with eligible criteria. Care was provided by nurses based on physicians’ instructions. In the first visit at home, a questionnaire on the quality of life was filled out by the patients or the nurses. The financial data of the medical records of the patients constituted the reference for the analysis of cost. After the intervention, the questionnaire on the quality of life was filled out by the patients once again and their satisfaction was measured. The data were statistically analyzed using the Python programming language and SPSS-16 at the 0. 05 level of significance. Results: The length of stay in the hospital for each patient decreased from 2. 1 days to 0. 9 days per month. The number of annual hospitalizations also decreased from 5 to 3, and the number of annual outpatient visits showed a reduction from 46 to 38 for each patient. The results of the patient satisfaction assessment also indicated that most of the patients were satisfied with the services provided to them. Conclusions: The results showed that our study was cost-effective. We suggest that interventions be performed on larger scales so that the results can be used in the future as services available to patients with heart failure.

heart failure (HF) is still a major problem worldwide with high morbidity and mortality rates. The recently developed medication for HF is still incapable of reducing its morbidity and mortality, and clinical data supporting the efficacy and safety of its mainstay therapy remain insufficient.Arginine-vasopressin (AVP) plays important roles in circulatory and water homeostasis, one of which is water retention through the V2 receptor. In patients with HF, there is an increased level of AVP, contributing to such symptoms as edema, dyspnea, and congestion. Tolvaptan as a selective V2 receptor antagonist, in addition to the conventional therapy, has been shown to cause an increase in net fluid loss, a decrease in body weight, and a reduction in the rate of HF exacerbation. Such evidence has been provided by the Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist (ACTIV) in Congestive heart failure (CHF), Efficacy of Vasopressin Antagonism in heart failure Outcome Study With Tolvaptan (EVEREST), Acute heart failure Volume Control Multicenter Randomized (AVCMA), and Study of Ascending Levels of Tolvaptan in hyponatremia 1and 2 (SALT-1 and SALT-2) trials. Tolvaptan can be an alternative diuretic in conjunction with other standard therapies for HF and has already been proved to be able to decrease morbidity and mortality, especially in HF patients with hyponatremia.